Vaccine

TFF Pharmaceuticals Announces Reverse Stock Split

Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023FORT WORTH, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE)…

2 years ago

Press Release: Availability of the Q4 2023 Memorandum for modelling purposes

Availability of the Q4 2023 Memorandum for modelling purposes Paris, France – December 15, 2023. Sanofi announced today that its…

2 years ago

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

  EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found…

2 years ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical…

2 years ago

Research for the Treatment of a ‘Black Sheep’ Cancer Moves to Human Clinical Trials

With $3.5 million in funding from the GI Research Foundation, a team at the MD Anderson Cancer Center explores a…

2 years ago

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025

CAMBRIDGE, MA / ACCESSWIRE / December 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to…

2 years ago

RETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence"…

2 years ago

Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)

Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence"…

2 years ago

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11,…

2 years ago